Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.

Nature communications - 24 Mar 2022

Zhang Peitao, Guan Haixia, Yuan Shukai, Cheng Huili, Zheng Jian, Zhang Zhenlei, Liu Yifan, Yu Yang, Meng Zhaowei, Zheng Xiangqian, Zhao Li

Abstract excerpt

MAPK signaling inhibitor (MAPKi) therapies show limited efficacy for advanced thyroid cancers despite constitutive activation of the signaling correlates with disease recurrence and persistence. Understanding how BRAF pathway stimulates tumorigenesis could lead to new therapeutic targets. Here, through genetic and pathological approaches, we demonstrate that BRAFV600E promotes thyroid cancer development by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ligands
Share to Myeloid-Derived Suppressor Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35332119
DOI: 10.1038/s41467-022-29000-5
PMCID: PMC8948260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.PMID 35332119Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells.Semantic proximity Read ↗

Functional Toll-like Receptor 4 Overexpression in Papillary Thyroid Cancer by MAPK/ERK–Induced ETS1 Transcriptional ActivitySemantic proximity Read ↗

Analysis of the Prognostic Value and Potential Molecular Mechanisms of TREM-1 Overexpression in Papillary Thyroid Cancer via Bioinformatics Methods.Semantic proximity Read ↗

PD-1 Blockade Delays Tumor Growth by Inhibiting an Intrinsic SHP2/Ras/MAPK Signalling in Thyroid Cancer CellsSemantic proximity Read ↗

BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression.Semantic proximity Read ↗

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsSemantic proximity Read ↗

Targeting miR‐31 represses tumourigenesis and dedifferentiation of BRAF V600E ‐associated thyroid carcinomaSemantic proximity Read ↗

RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.Semantic proximity Read ↗

Papillary Thyroid Carcinoma with Terminal Immune Exhaustion Phenotype Correlates with Increased Risk of Lymph Node Metastasis: A Combined Flow Cytometry and TCGA Validation StudySemantic proximity Read ↗

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Semantic proximity Read ↗

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.